ADAP logo

Adaptimmune Therapeutics (ADAP) Company Overview

Profile

Full Name:

Adaptimmune Therapeutics plc

Sector:

Healthcare

Industry:

Biotechnology

Country:

United Kingdom

IPO:

May 6, 2015

Indexes:

Not included

Description:

Adaptimmune Therapeutics is a biotechnology company focused on developing T-cell therapies for cancer treatment. They use a unique approach to harness the body’s immune system to target and destroy cancer cells, aiming to improve outcomes for patients with various types of cancer.

Key Details

Price

$0.61

Annual Revenue

$60.28 M(+122.05% YoY)

Annual EPS

-$0.54(+47.06% YoY)

Annual ROE

-187.61%

Beta

1.43

Events Calendar

Earnings

Next earnings date:

Mar 6, 2025

Recent quarterly earnings:

Nov 13, 2024

Recent annual earnings:

Mar 6, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Nov 27, 24 Mizuho
Outperform
Nov 19, 24 HC Wainwright & Co.
Buy
Nov 15, 24 Guggenheim
Buy
Nov 14, 24 HC Wainwright & Co.
Buy
Aug 13, 24 HC Wainwright & Co.
Buy
Aug 5, 24 HC Wainwright & Co.
Buy
Jul 30, 24 HC Wainwright & Co.
Buy
May 30, 24 Scotiabank
Sector Outperform
May 17, 24 Mizuho
Buy
Aug 10, 23 EF Hutton
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
ADAP
newsfilecorp.comJanuary 13, 2025

The Company will present at the Annual J.P. Morgan Healthcare Conference, providing business updates on its sarcoma franchise and other cell therapy pipeline assets Adaptimmune Allo-T program to be featured at the Biotech ShowCase (TM) and the Wuxi Global Forum 2025 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 13, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that letetresgene autoleucel (lete-cel), has been granted breakthrough therapy designation by the U.S. FDA for the treatment of patients with unresectable or metastatic myxoid/round cell liposarcoma (MRCLS) who have received prior anthracycline-based chemotherapy, are positive for HLA-A*02:01, HLA-A*02:05, or HLA-A*02:06, and whose tumor expresses the NY-ESO-1 antigen.

Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript
Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript
Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript
ADAP
seekingalpha.comNovember 13, 2024

Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Dan Od-Cohen - IR Adrian Rawcliffe - CEO Gavin Wood - CFO Dennis Williams - SVP, Late Stage Development Conference Call Participants Marc Frahm - TD Cowen Tony Butler - Rodman & Renshaw Paul Jeng - Guggenheim Yen-Der Li - Leerink Partners Graig Suvannavejh - Mizuho Securities Arthur He - H.C. Wainwright George Farmer - Scotiabank Michael Kim - Zacks Small Cap Research Peter Lawson - Barclays Operator Hello and welcome to the Adaptimmune Therapeutics Third Quarter 2024 Results Conference Call.

Adaptimmune to Participate in Scientific and Medical Conferences this November and December
Adaptimmune to Participate in Scientific and Medical Conferences this November and December
Adaptimmune to Participate in Scientific and Medical Conferences this November and December
ADAP
newsfilecorp.comNovember 5, 2024

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 5, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced presence and presentations at key scientific and medical conferences in November and December. Society for Immunotherapy of Cancer (SITC) 39 th annual meeting, November 6-10, Houston, TX Podium presentation: "Delivering on the Promise of Cell Therapies for Solid Tumors: T-cell Therapy for Synovial Sarcoma" / Jo Brewer, PhD, Chief Scientific Officer, Adaptimmune.

Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024
Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024
Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024
ADAP
newsfilecorp.comOctober 31, 2024

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 31, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the third quarter ended September 30, 2024, after the US markets close on Wednesday, November 13, 2024. Following the announcement, the Company will host a live webcast at 4:30 p.m.

Adaptimmune to Participate in Two Bank Conferences this September
Adaptimmune to Participate in Two Bank Conferences this September
Adaptimmune to Participate in Two Bank Conferences this September
ADAP
newsfilecorp.comAugust 28, 2024

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 28, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in two investment bank conferences this September. Wells Fargo Healthcare Conference, Boston, MA Fireside chat: Wednesday September 4, 2024, at 4:30 PM EDT.

Adaptimmune Therapeutics plc (ADAP) Q2 2024 Earnings Call Transcript
Adaptimmune Therapeutics plc (ADAP) Q2 2024 Earnings Call Transcript
Adaptimmune Therapeutics plc (ADAP) Q2 2024 Earnings Call Transcript
ADAP
seekingalpha.comAugust 12, 2024

Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q2 2024 Earnings Conference Call August 12, 2024 8:00 AM ET Company Participants Dan Od-Cohen - Investor Relations Adrian Rawcliffe - Chief Executive Officer Cintia Piccina - Chief Commercial Officer Joanna Brewer - Chief Scientific Officer Dennis Williams - Senior Vice President, Late Stage Development John Lunger - Chief Patient Supply Officer Elliot Norry - Chief Medical Officer Conference Call Participants Marc Frahm - TD Cowen Matthew Cowper - Leerink Partners Paul Jeng - Guggenheim Securities Tony Butler - Rodman & Renshaw Graig Suvannavejh - Mizuho Securities George Farmer - Scotiabank Arthur He - H.C. Wainwright Kuan-Hung Lin - Wells Fargo Michael Kim - Zacks Small-Cap Research Alexandre Bouilloux - Barclays Operator Good day and welcome to the Adaptimmune Second Quarter 2024 Conference Call.

Adaptimmune Reports Q2 2024 Financial and Business Updates
Adaptimmune Reports Q2 2024 Financial and Business Updates
Adaptimmune Reports Q2 2024 Financial and Business Updates
ADAP
newsfilecorp.comAugust 12, 2024

Adaptimmune received U.S. FDA accelerated approval of Tecelra® (afami-cel), the first approved engineered cell therapy for a solid tumor Patients can begin treatment journey; biomarker testing available; Adaptimmune systems ready to receive orders At the end of Q2, Adaptimmune had Total Liquidity[1] of $214.8 million Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 12, 2024) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reports financial results and business updates for the second quarter ended June 30, 2024. The Company will host a live webcast at 8:00 a.m.

Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024
Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024
Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024
ADAP
newsfilecorp.comAugust 5, 2024

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 5, 2024) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the second quarter ended June 30, 2024, before the US markets open on Monday, August 12, 2024. Following the announcement, the Company will host a live webcast at 8:00 a.m.

US FDA approves Adaptimmune's gene therapy for rare type of cancer
US FDA approves Adaptimmune's gene therapy for rare type of cancer
US FDA approves Adaptimmune's gene therapy for rare type of cancer
ADAP
reuters.comAugust 2, 2024

The U.S. Food and Drug Administration said on Friday it has approved Adaptimmune's first-of-its-kind gene therapy to treat adult patients with a rare type of cancer that affects soft tissues who have received prior chemotherapy.

Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor
Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor
Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor
ADAP
businesswire.comAugust 1, 2024

PHILADELPHIA & OXFORD, England--(BUSINESS WIRE)--Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced U.S. Food and Drug Administration (FDA) accelerated approval of TECELRA® (afamitresgene autoleucel) for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses.

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the ticker symbol for Adaptimmune Therapeutics?
  • Does Adaptimmune Therapeutics pay dividends?
  • What sector is Adaptimmune Therapeutics in?
  • What industry is Adaptimmune Therapeutics in?
  • What country is Adaptimmune Therapeutics based in?
  • When did Adaptimmune Therapeutics go public?
  • Is Adaptimmune Therapeutics in the S&P 500?
  • Is Adaptimmune Therapeutics in the NASDAQ 100?
  • Is Adaptimmune Therapeutics in the Dow Jones?
  • When was Adaptimmune Therapeutics's last earnings report?
  • When does Adaptimmune Therapeutics report earnings?
  • Should I buy Adaptimmune Therapeutics stock now?

What is the ticker symbol for Adaptimmune Therapeutics?

The ticker symbol for Adaptimmune Therapeutics is NASDAQ:ADAP

Does Adaptimmune Therapeutics pay dividends?

No, Adaptimmune Therapeutics does not pay dividends

What sector is Adaptimmune Therapeutics in?

Adaptimmune Therapeutics is in the Healthcare sector

What industry is Adaptimmune Therapeutics in?

Adaptimmune Therapeutics is in the Biotechnology industry

What country is Adaptimmune Therapeutics based in?

Adaptimmune Therapeutics is headquartered in United Kingdom

When did Adaptimmune Therapeutics go public?

Adaptimmune Therapeutics's initial public offering (IPO) was on May 6, 2015

Is Adaptimmune Therapeutics in the S&P 500?

No, Adaptimmune Therapeutics is not included in the S&P 500 index

Is Adaptimmune Therapeutics in the NASDAQ 100?

No, Adaptimmune Therapeutics is not included in the NASDAQ 100 index

Is Adaptimmune Therapeutics in the Dow Jones?

No, Adaptimmune Therapeutics is not included in the Dow Jones index

When was Adaptimmune Therapeutics's last earnings report?

Adaptimmune Therapeutics's most recent earnings report was on Nov 13, 2024

When does Adaptimmune Therapeutics report earnings?

The next expected earnings date for Adaptimmune Therapeutics is Mar 6, 2025

Should I buy Adaptimmune Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions